Dyne Therapeutics, Inc. Operating Cash Flow
Dyne Therapeutics, Inc. (DYN) reported Operating Cash Flow of -$275.21 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-07-29
- Dyne Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$130.29M.
- Dyne Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$144.92M.
- Dyne Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$111.83M.
- Dyne Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$90.78M.
- Dyne Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$403.21M.
- Dyne Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$292.37M.
- Dyne Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$188.16M.
- Dyne Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$153.65M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$130.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | -$275.21M 10-Q · filed 2026-07-29 | -$387.04M derived: sum of 3 quarters · filed 2026-07-29 | -$477.82M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | -$144.92M 10-Q · filed 2026-05-11 | -$256.75M derived: sum of 2 quarters · filed 2026-05-11 | -$347.53M derived: sum of 3 quarters · filed 2026-05-11 | -$442.24M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | -$111.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$202.61M derived: sum of 2 quarters · filed 2026-03-02 | -$297.31M derived: sum of 3 quarters · filed 2026-07-29 | -$403.21M 10-K · filed 2026-03-02 |
| 2025-09-30 | -$90.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$185.48M derived: sum of 2 quarters · filed 2026-07-29 | -$291.38M 10-Q · filed 2025-11-05 | -$375.71M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | -$94.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | -$200.60M 10-Q · filed 2026-07-29 | -$284.93M derived: sum of 3 quarters · filed 2026-07-29 | -$359.56M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | -$105.89M 10-Q · filed 2026-05-11 | -$190.23M derived: sum of 2 quarters · filed 2026-05-11 | -$264.86M derived: sum of 3 quarters · filed 2026-05-11 | -$319.73M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$84.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$158.96M derived: sum of 2 quarters · filed 2026-03-02 | -$213.83M derived: sum of 3 quarters · filed 2026-03-02 | -$292.37M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$74.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$129.50M derived: sum of 2 quarters · filed 2025-11-05 | -$208.03M 10-Q · filed 2025-11-05 | -$243.04M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | -$54.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-28 | -$133.41M 10-Q · filed 2025-07-28 | -$168.41M derived: sum of 3 quarters · filed 2026-03-02 | -$219.01M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | -$78.54M 10-Q · filed 2025-05-08 | -$113.54M derived: sum of 2 quarters · filed 2026-03-02 | -$164.15M derived: sum of 3 quarters · filed 2026-03-02 | -$219.79M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | -$35.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$85.61M derived: sum of 2 quarters · filed 2026-03-02 | -$141.25M derived: sum of 3 quarters · filed 2026-03-02 | -$188.16M 10-K · filed 2026-03-02 |
| 2023-09-30 | -$50.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$106.24M derived: sum of 2 quarters · filed 2024-11-12 | -$153.15M 10-Q · filed 2024-11-12 | -$182.34M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$55.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$102.55M 10-Q · filed 2024-08-12 | -$131.74M derived: sum of 3 quarters · filed 2025-02-27 | -$174.55M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$46.91M 10-Q · filed 2024-05-02 | -$76.10M derived: sum of 2 quarters · filed 2025-02-27 | -$118.91M derived: sum of 3 quarters · filed 2025-02-27 | -$149.81M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$29.19M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$72.00M derived: sum of 2 quarters · filed 2025-02-27 | -$102.91M derived: sum of 3 quarters · filed 2025-02-27 | -$153.65M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$42.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-30 | -$73.71M derived: sum of 2 quarters · filed 2023-10-30 | -$124.45M 10-Q · filed 2023-10-30 | -$152.52M derived: sum of 4 quarters · filed 2023-10-30 |
| 2022-06-30 | -$30.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$81.65M 10-Q · filed 2023-08-03 | -$109.72M derived: sum of 3 quarters · filed 2023-08-03 | -$136.67M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$50.74M 10-Q · filed 2023-05-11 | -$78.81M derived: sum of 2 quarters · filed 2023-05-11 | -$105.76M derived: sum of 3 quarters · filed 2023-05-11 | -$151.91M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$28.07M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | -$55.02M derived: sum of 2 quarters · filed 2023-03-02 | -$101.17M derived: sum of 3 quarters · filed 2023-03-02 | -$119.56M 10-K · filed 2023-03-02 |
| 2021-09-30 | -$26.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$73.10M derived: sum of 2 quarters · filed 2022-11-03 | -$91.50M 10-Q · filed 2022-11-03 | -$111.53M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$46.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$64.54M 10-Q · filed 2022-08-04 | -$84.58M derived: sum of 3 quarters · filed 2022-08-04 | -$96.47M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$18.39M 10-Q · filed 2022-05-02 | -$38.43M derived: sum of 2 quarters · filed 2022-05-02 | -$50.31M derived: sum of 3 quarters · filed 2022-05-02 | -$57.61M derived: sum of 4 quarters · filed 2022-05-02 |
| 2020-12-31 | -$20.04M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$31.92M derived: sum of 2 quarters · filed 2022-03-10 | -$39.22M derived: sum of 3 quarters · filed 2022-03-10 | -$46.51M 10-K · filed 2022-03-10 |
| 2020-09-30 | -$11.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$19.18M derived: sum of 2 quarters · filed 2021-11-04 | -$26.47M 10-Q · filed 2021-11-04 | -$30.49M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | -$7.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$14.59M 10-Q · filed 2021-08-05 | -$18.60M derived: sum of 3 quarters · filed 2021-08-05 | |
| 2020-03-31 | -$7.29M 10-Q · filed 2021-05-06 | -$11.30M derived: sum of 2 quarters · filed 2021-05-06 | ||
| 2019-12-31 | -$4.01M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | -$11.83M 10-K · filed 2021-03-04 | ||
| 2019-09-30 | -$7.82M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |